Responses
Regular and Young Investigator Award Abstracts
Cellular Therapies
268 Development of FT825/ONO-8250: an off-the-shelf CAR-T cell with preferential HER2 targeting and engineered to enable multi-antigen targeting, improve trafficking, and overcome immunosuppression
Compose a Response to This Article
Other responses
No responses have been published for this article.
